論文 - 詳細
| RRC ID | 63598 |
|---|---|
| 著者 | Hirata H, Kuwatani M, Nakajima K, Kodama Y, Yoshikawa Y, Ogawa M, Sakamoto N. |
| タイトル | Near-infrared photoimmunotherapy (NIR-PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes. |
| ジャーナル | Cancer Sci |
| Abstract |
Near-infrared photoimmunotherapy (NIR-PIT) is a novel therapy for cancers that uses NIR light and antibody-photosensitizer (IR700) conjugates. However, it is difficult to deliver NIR light into the bile duct for cholangiocarcinoma (CCA) from the conventional extracorporeal apparatus. Thus, in this study, we developed a dedicated catheter with light emitting diodes (LEDs) that supersedes conventional external irradiation devices; we investigated the therapeutic effect of NIR-PIT for CCA using the novel catheter. The new catheter was designed to be placed in the bile duct and a temperature sensor was attached to the tip of the catheter to avoid thermal burn. An anti-epidermal growth factor receptor (EGFR) antibody, Panitumumab-IR700 conjugate or anti-human epidermal growth factor receptor type 2 (HER2) antibody, Trastuzumab-IR700 conjugate, was used with EGFR- or HER2-expressing cell lines, respectively. The in vitro efficacy of NIR-PIT was confirmed in cultured cells; the capability of the new catheter for NIR-PIT was then tested in a mouse tumor model. NIR-PIT via the developed catheter treated CCA xenografts in mice. NIR-PIT had an effect in Panitumumab-IR700 conjugate- and Trastuzumab-IR700 conjugate-treated CCA cells that depended on the receptor expression level. Tumor growth was significantly suppressed in mice treated with NIR-PIT using the novel catheter compared with controls (P < .01). NIR-PIT was an effective treatment for EGFR- and HER2-expressing CCA cells, and the novel catheter with mounted LEDs was useful for NIR-PIT of CCA. |
| 巻・号 | 112(2) |
| ページ | 828-838 |
| 公開日 | 2021-2-1 |
| DOI | 10.1111/cas.14780 |
| PMID | 33345417 |
| PMC | PMC7894014 |
| MeSH | Animals Bile Duct Neoplasms / therapy* Catheters Cell Line, Tumor Cholangiocarcinoma / therapy* Female Humans Immunotherapy / instrumentation* Immunotherapy / methods Infrared Rays / therapeutic use Low-Level Light Therapy / instrumentation* Low-Level Light Therapy / methods Mice Mice, Inbred BALB C Mice, Nude Panitumumab / pharmacology Photosensitizing Agents / pharmacology Trastuzumab / pharmacology Xenograft Model Antitumor Assays |
| IF | 4.966 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | |
| 各媒体での言及数の合計 | 1 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | HuCCT1(RCB1960) YSCCC(RCB1549) TFK-1(RCB2537) |